In a Law360 article, health care partner Margaux Hall, who leads the firm’s drug pricing and price reporting group, and health care associate Emma Coreno examine drug pricing policy trends in Trump administration and new Congress. They predict that 2025 will be another busy year for drug pricing across all branches of government, with legal developments affecting the federal healthcare program and commercial market segments.
The article analyzes key drug pricing legal and policy issues to watch in 2025, including the Inflation Reduction Act, the Section 340B program and contract pharmacy arrangements, the BIOSECURE Act, pharmacy benefit manager scrutiny, state prescription drug affordability boards, and Center for Medicare and Medicaid Innovation demonstrations.
The authors note that drug pricing remains a bipartisan issue that is likely to have enduring importance. They note that the “priceless” question across administrations and congresses is how to provide incentives for robust pharmaceutical innovation and also allow patients to have affordable access to that innovation.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.